Does the use of hormonal contraceptives affect bone mineral density?

References

• WHO. Medical eligibility criteria for contraceptive use (3rd Edition). WHO, Geneva, Switzerland (2004).
   Google Scholar
• Johnston CC Jr, Slemenda CW, Melton LJ 3rd. Clinical use of bone densitometry. N. Engl. J. Med.324, 1105–1109 (1991).
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A et al. Smoking and fracture risk: a meta-analysis. Osteoporos. Int.16, 155–162 (2005).
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Johnell O et al. Alcohol intake as a risk factor for fracture. Osteoporos. Int.16, 737–742 (2005).
   PubMed Web of Science ®Google Scholar
• Karlsson C, Obrant KJ, Karlsson M. Pregnancy and lactation confer reversible bone loss in humans. Osteoporos. Int.12, 828–834 (2001).
   PubMed Web of Science ®Google Scholar
• Bagger YZ, Tanko LB, Alexandersen P et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone34, 728–735 (2004).
   PubMed Web of Science ®Google Scholar
• d'Arcangues C. WHO statement on hormonal contraception and bone health. Contraception73, 443–444 (2006).
   PubMed Web of Science ®Google Scholar
• Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br. Med J.312, 1254–1259 (1996).
   PubMed Web of Science ®Google Scholar
• Melton LJ 3rd, Crowson C, O’Fallon WM, Wahner HW, Riggs BL. Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J. Bone Miner. Res.18, 312–318 (2003).
   PubMed Web of Science ®Google Scholar
• Sandor T, Felsenberg D, Brown E. Comments on the hypotheses underlying fracture risk assessment in osteoporosis as proposed by the World Health Organization. Calcif. Tissue Int.64, 267–270 (1999).
   PubMed Web of Science ®Google Scholar
• Schonau E. The peak bone mass concept: is it still relevant? Pediatr. Nephrol.19, 825–831 (2004).
   PubMed Web of Science ®Google Scholar
• Recker RR, Davies KM, Hinders SM, Heaney RP, Stegman MR, Kimmel DB. Bone gain in young adult women. JAMA17, 2403–2408 (1992).
   Google Scholar
• US FDA. Black box warning on Depo-Provera contraceptive injection. November 17 (2004).
   Google Scholar
• Duff G. Updated prescribing advice on the effect of Depo-Provera contraception on bones HSS (MD) 39–2004. November 18 (2004).
   Google Scholar
• Kaunitz AM. Depo-Provera’s black box: time to reconsider? Contraception72, 165–167 (2005).
   PubMed Web of Science ®Google Scholar
• Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, Kaunitz AM, Society for Adolescent Medicine. Depot medroxyprogesterone acetate and bone mineral density in adolescents. The Black Box Warning: a position paper of the Society for Adolescent Medicine. J. Adolesc. Health39, 296–301 (2006).
   PubMed Web of Science ®Google Scholar
• Cundy T, Cornish J, Evans MC, Roberts H, Reid IR. Recovery of bone density in women who stop using medroxyprogesterone acetate. Br. Med. J.308, 247–248 (1994).
   PubMed Web of Science ®Google Scholar
• WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ. Tech. Rep. Ser.843, 1–290 (1994).
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A et al. The use of multiple sites for the diagnosis of osteoporosis. Osteoporos. Int.17, 527–534 (2006).
   PubMed Web of Science ®Google Scholar
• De Laet C, Kanis JA, Oden A et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos. Int.16, 1330–1338 (2005).
   PubMed Web of Science ®Google Scholar
• Doren M, Nilsson JA, Johnell O. Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. Hum. Reprod.18, 1737–1746 (2003).
   PubMed Web of Science ®Google Scholar
• Compston JE. Sex steroids and bone. Physiol. Rev.81, 419–447 (2001).
   PubMed Web of Science ®Google Scholar
• Polatti F, Perotti F, Filippa N, Gallina D, Nappi RE. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception51, 221–224 (1995).
   PubMed Web of Science ®Google Scholar
• Davies MC, Hall ML, Jacobs HS. Bone mineral loss in young women with amenorrhoea. Br. Med. J.301, 790–793 (1990).
   PubMed Web of Science ®Google Scholar
• Cromer BA, Stager M, Bonny A et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J. Adolesc. Health35, 434–441 (2004).
   PubMed Web of Science ®Google Scholar
• Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet. Gynecol.103, 899–906 (2004).
   PubMed Web of Science ®Google Scholar
• Lara-Torre E, Edwards CP, Perlman S, Hertweck SP. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J. Pediatr. Adolesc. Gynecol.17, 17–21 (2004).
   PubMedGoogle Scholar
• Hartard M, Kleinmond C, Luppa P et al. Comparison of the skeletal effects of the progestogens desogestrel and levonorgestrel in oral contraceptive preparations in young women: controlled, open, partly randomized investigation over 13 cycles. Contraception74, 367–375 (2006).
   PubMed Web of Science ®Google Scholar
• Nappi C, Di Spiezio Sardo A, Acunzo G et al. Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception67, 355–359 (2003).
   PubMed Web of Science ®Google Scholar
• Nappi C, Di Spiezio Sardo A, Greco E, Tommaselli GA, Giordano E, Guida M. Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density. Obstet. Gynecol.105, 53–60 (2005).
   PubMed Web of Science ®Google Scholar
• Reed SD, Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Longitudinal changes in bone density in relation to oral contraceptive use. Contraception68, 177–182 (2003).
   PubMed Web of Science ®Google Scholar
• Martins SL, Curtis KM, Glasier AF. Combined hormonal contraception and bone health: a systematic review. Contraception73, 445–469 (2006).
   PubMed Web of Science ®Google Scholar
• Recker RR, Davies KM, Hinders SM, Heaney RP, Stegman MR, Kimmel DB. Bone gain in young adult women. JAMA268, 2403–2408 (1992).
   PubMed Web of Science ®Google Scholar
• Petitti DB, Piaggio G, Mehta S, Cravioto MC, Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet. Gynecol.95, 736–744 (2000).
   PubMed Web of Science ®Google Scholar
• Barad D, Kooperberg C, Wactawski-Wende J, Liu J, Hendrix S, Watts N. Prior oral contraception and postmenopausal fracture: a Women’s Health Initiative observational cohort study. Fertil. Steril.84, 374–383 (2005).
   PubMed Web of Science ®Google Scholar
• Vessey M, Mant J, Painter R. Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study. Contraception57, 231–235 (1998).
   PubMed Web of Science ®Google Scholar
• Cooper C, Hannaford P, Croft P, Kay CR. Oral contraceptive pill use and fractures in women: a prospective study. Bone14, 41–45 (1993).
   PubMed Web of Science ®Google Scholar
• Michaelsson K, Baron JA, Farahmand BY, Persson I, Ljunghall S. Oral-contraceptive use and risk of hip fracture: a case–control study. Lancet353, 1481–1484 (1999).
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Oral contraceptive use and risk of fractures. Contraception73, 571–576 (2006).
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Cappagli B, Lazzarini V, Ciaponi M, Fruzzetti F, Genazzani AR. Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density. Maturitas54, 176–180 (2006).
   PubMed Web of Science ®Google Scholar
• Strokosch GR, Friedman AJ, Wu SC, Kamin M. Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study. J. Adolesc. Health.39, 819–827 (2006).
   PubMed Web of Science ®Google Scholar
• Warren MP, Miller KK, Olson WH, Grinspoon SK, Friedman AJ. Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study. Contraception72, 206–211 (2005).
   PubMed Web of Science ®Google Scholar
• Rome E, Ziegler J, Secic M et al. Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive. J. Pediatr. Adolesc. Gynecol.17, 373–377 (2004).
   PubMedGoogle Scholar
• Endrikat J, Mih E, Dusterberg B et al. A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 microg or 30 microg ethinylestradiol in combination with levonorgestrel on bone mineral density. Contraception69, 179–187 (2004).
   PubMed Web of Science ®Google Scholar
• Paoletti AM, Orru M, Lello S et al. Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol: observational study in young postadolescent women. Contraception70, 293–298 (2004).
   PubMed Web of Science ®Google Scholar
• Massai R, Makarainen L, Kuukankorpi A, Klipping C, Duijkers I, Dieben T. The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women. Hum. Reprod.20, 2764–2768 (2005).
   PubMed Web of Science ®Google Scholar
• Kaunitz AM. Injectable contraception. New and existing options. Obstet. Gynecol. Clin. North Am.27, 741–780 (2000).
   PubMed Web of Science ®Google Scholar
• Upadhyay UD. New contraceptive choices. Population Reports, M. Series, No. 19. Baltimore: Johns Hopkins Bloomberg School of Public Health, The INFO Project. April, 2005.
   Google Scholar
• von Kesseru E, Etchepareborda JJ, Wikinski R, Beier S. Premenopause contraception with monthly injectable Mesigyna with special emphasis on serum lipid and bone density patterns. Contraception61, 317–322 (2000).
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Juliato CT, Villarreal M, Sobreira-Lima B, Simões JA, dos Santos Fernandes AM. Bone mineral density in users of two kinds of once-a-month combined injectable contraceptives. Contraception74, 259–263 (2006).
   PubMed Web of Science ®Google Scholar
• Fraser IS, Weisberg E. A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. Med. J. Aust.1(1 Suppl.), 3–19 (1981).
   PubMed Web of Science ®Google Scholar
• Gbolade B, Ellis S, Murby B, Randall S, Kirkman R. Bone density in long term users of depot medroxyprogesterone acetate. Br. J. Obstet. Gynaecol.105, 790–794 (1998).
   PubMedGoogle Scholar
• Cundy T, Cornish J, Roberts H, Elder H, Reid IR. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet. Gynecol.92, 569–573 (1998).
   PubMed Web of Science ®Google Scholar
• Tang OS, Tang G, Yip P, Li B, Fan S. Long-term depot-medroxyprogesterone acetate and bone mineral density. Contraception59, 25–29 (1999).
   PubMed Web of Science ®Google Scholar
• Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology13, 581–587 (2002).
   PubMed Web of Science ®Google Scholar
• Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. Contraception73, 470–487 (2006).
   PubMed Web of Science ®Google Scholar
• Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch. Pediatr. Adolesc. Med.159, 139–144 (2005).
   PubMed Web of Science ®Google Scholar
• Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Contraception69, 99–104 (2004).
   PubMed Web of Science ®Google Scholar
• Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil. Steril.82, 1580–1586 (2004).
   PubMed Web of Science ®Google Scholar
• Clark MK, Sowers MF, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil. Steril.86, 1466–1474 (2006).
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25–35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception74, 90–99 (2006).
   PubMed Web of Science ®Google Scholar
• Tang OS, Tang G, Yip PS, Li B. Further evaluation on long-term depot-medroxyprogesterone acetate use and bone mineral density: a longitudinal cohort study. Contraception62, 161–164 (2000).
   PubMed Web of Science ®Google Scholar
• Lappe JM, Stegman MR, Recker RR. The impact of lifestyle factors on stress fractures in female army recruits. Osteoporos. Int.12, 35–42 (2001).
   PubMed Web of Science ®Google Scholar
• Harkins GJ, Davis GD, Dettori J, Hibbert ML, Hoyt RA. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report. J. Reprod. Med.44, 309–312 (1999).
   PubMed Web of Science ®Google Scholar
• Albertazzi P, Bottazzi M, Steel SA. Bone mineral density and depot medroxyprogesterone acetate. Contraception73, 577–583 (2006).
   PubMed Web of Science ®Google Scholar
• Cundy T, Ames R, Horne A et al. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J. Clin. Endocrinol. Metab.88, 78–81 (2003).
   PubMed Web of Science ®Google Scholar
• Cundy T, Cornish J, Roberts H, Reid IR. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am. J. Obstet. Gynecol.186, 978–983 (2002).
   PubMed Web of Science ®Google Scholar
• Recker R, Lappe J, Davies K, Heaney R. Characterization of perimenopausal bone loss: a prospective study. J. Bone Miner. Res.15, 1965–1973 (2000).
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception65, 129–132 (2002).
   PubMed Web of Science ®Google Scholar
• Luukkainen T, Lähteenmäki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann. Med.22, 85–90 (1990).
   PubMed Web of Science ®Google Scholar
• Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet. Gynecol. Scand.78, 716–721 (1999).
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Espejo-Arce X, Hidalgo MM, Hidalgo-Regina C, Teatin-Juliato C, Petta CA. A cross-sectional study of the forearm bone density of long-term users of levonorgestrel-releasing intrauterine system. Hum. Reprod.21, 1316–1319 (2006).
   PubMed Web of Science ®Google Scholar
• Barbosa I, Olsson SE, Odlind V, Goncalves T, Coutinho E. Ovarian function after seven years’ use of a levonorgestrel IUD. Adv. Contracept.11, 85–95 (1995).
   PubMedGoogle Scholar
• Bahamondes L, Hidalgo M, Petta CA, Diaz J, Espejo-Arce X, Monteiro-Dantas C. Enlarged ovarian follicles in users of a levonorgestrel-releasing intrauterine system and contraceptive implant. J. Reprod. Med.48, 637–640 (2003).
   PubMed Web of Science ®Google Scholar
• Nilsson CG, Lahteenmaki PL, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil. Steril.41, 52–55 (1984).
   PubMed Web of Science ®Google Scholar
• Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br. Med. J.312, 1254–1259 (1996).
   PubMed Web of Science ®Google Scholar
• Curtis KM. Safety of implantable contraceptives for women: data from observational studies. Contraception65, 85–96 (2002).
   PubMed Web of Science ®Google Scholar
• Naessen T, Olsson SE, Gudmundson J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception52, 35–39 (1995).
   PubMed Web of Science ®Google Scholar
• Di X, Li Y, Zhang C, Jiang J, Gu S. Effects of levonorgestrel-releasing subdermal contraceptive implants on bone density and bone metabolism. Contraception60, 161–166 (1999).
   PubMed Web of Science ®Google Scholar
• Taneepanichskul S, Intaraprasert S, Theppisai U, Chaturachinda K. Bone mineral density during long-term treatment with Norplant implants and depot medroxyprogesterone acetate. A cross-sectional study of Thai women. Contraception56, 153–155 (1997).
   PubMed Web of Science ®Google Scholar
• Vanderjagt DJ, Sagay AS, Imade GE, Farmer SE, Glew RH. Effect of Norplant contraceptive on the bones of Nigerian women as assessed by quantitative ultrasound and serum markers of bone turnover. Contraception72, 212–216 (2005).
   PubMed Web of Science ®Google Scholar
• Volpe A, Amrham A, Cagnacci A, Battaglia C. Biochemical aspects of hormonal contraception: effects on bone metabolism. Eur. J. Contracept. Reprod. Health Care2, 123–126 (1997).
   PubMedGoogle Scholar
• Diaz S, Reyes MV, Zepeda A et al. Norplant implants and progesterone vaginal rings do not affect maternal bone turnover and density during lactation and after weaning. Hum. Reprod.14, 2499–2505 (1999).
   PubMed Web of Science ®Google Scholar
• Croxatto HB. Progestin implants for female contraception. Contraception65, 15–19 (2002).
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Monteiro-Dantas C, Espejo-Arce X et al. A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants. Hum. Reprod.21, 466–470 (2006).
   PubMed Web of Science ®Google Scholar
• Beerthuizen R, van Beek A, Massai R, Makarainen L, Hout J, Bennink HC. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum. Reprod.15, 118–122 (2000).
   PubMed Web of Science ®Google Scholar
• Makarainen L, van Beek A, Tuomivaara L, Asplund B, Coelingh Bennink H. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil. Steril.69, 714–721 (1998).
   PubMed Web of Science ®Google Scholar
• Caird LE, Reid-Thomas V, Hannan WJ, Gow S, Glasier AF. Oral progestogen-only contraception may protect against loss of bone mass in breast-feeding women. Clin. Endocrinol. (Oxf.)41, 739–745 (1994).
   PubMed Web of Science ®Google Scholar
• Beksinska ME, Smit JA, Kleinschmidt I, Farley TM, Mbatha F. Bone mineral density in women aged 40–49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception. Contraception71, 170–175 (2005).
   PubMed Web of Science ®Google Scholar
• Prior JC. Progesterone as a bone-trophic hormone. Endocr. Rev.11, 386–398 (1990).
   PubMed Web of Science ®Google Scholar
• Heiss CJ, Sanborn CF, Nichols DL, Bonnick SL, Alford BB. Associations of body fat distribution, circulating sex hormones, and bone density in post-menopausal women. J. Clin. Endocrinol. Metab.80, 1591–1596 (1995).
   PubMed Web of Science ®Google Scholar
• Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin. Endocrinol. (Oxf.)49, 615–618 (1998).
   PubMed Web of Science ®Google Scholar
• Banks E, Berrington A, Casabonne D. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. Br. J. Obstet. Gynaecol.108, 1214–1221 (2001).
   Google Scholar
• Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J. Pediatr.129, 671–676 (1996).
   PubMed Web of Science ®Google Scholar
• CDC. Achievements in public health, 1900–1999: Family Planning. JAMA283, 326–331 (2000).
   PubMed Web of Science ®Google Scholar